Archive

Abstract

Background: Non-steroidal anti-inflammatory drugs (NSAIDs) play a crucial role in the treatment of Ankylosing spondylitis. Cost and drug toxicity frequently deter the long-term use of anti-tumor necrosis factor agents in Ankylosing spondylitis. Methodology: The trial was conducted on 50 patients with symptomatic active chronic AS who received rheumatology therapy. Every two weeks 40mg Adalimumab was administered 6 injections for subcutaneous (10 weeks). As per follow-up, they did not achieve AS response criteria by week 12. RCT was conducted on 215 patients who participated in 6 weeks & compared celecoxib, ketoprofen, and placebo were randomly allocated continuous treatment with NSAIDs or demand treatment after over half of the patients continued to improve. Results: Four clinical trials were conducted on celecoxib, Adalimumab, ketoprofen, and placebo Patients experienced early and significant improvement in pain, NSAIDs requirement, function, and several indices ASAS 20 and 40, ASAS partial remission after discontinuing injections. At weeks 12 and 48, 84% and 52% of patients showed ASAS 20 improvement. Most AS patients are at low risk of cardiovascular and gastrointestinal complications. Conclusions: A study was conducted by a rheumatologist for 215 patients a 10-week course of NSAIDS was given to patients after 10 week course there was early improvement that often lasted for 24 weeks. Continuous use of NSAIDs reduces pain without increasing toxicity.

Keywords

Ankylosing spondylitis, NSAIDs, Treatment

Reference

  1. Zonchvan der Linden S, van Tubergen A, Hidding A (2002) Physiotherapy in ankylosing spondylitis: what is the evidence? Clin Exp Rheumatol 20[6 Suppl 28]: S60- S66
  2. Miceli-Richard C, Dougados M (2002) NSAIDS in ankylosing spondylitis. Clin Exp Rheumatol 20[6 Suppl 28]:S65-S66
  3. Dougados M (2001) Treatment of Spondyloarthropathies. Recent advances and prospects in 2001. Joint Bone Spine 68(6):557- 563
  4. Braun J, Sieper J (2004) Biological therapies in the spondyloarthritides-the current state. Rheumatology 43(9): 1072-1084
  5. Amor B, Dougados M, Mijiyawa M (1990) Criteria of the classification of spondyloarthropathies Rev Rhum Mal Osteoartic 57(2): 85-89
  6. Laine L (2003) Gastrointestinal effects of NSAIDs and coxibs. J Pain Symptom Manage 25[2 Suppl]:S32-S40
  7. Zochling J, Bohl-Buhler MHJ, Baralikos X, Feldtkeller E, Braun J (2005) The high prevalence of infections and allergic symptoms in patients with ankylosing spondylitis is associated with clinical symptoms. Clin Rheumatol Online First, DOI: 10. 1007/s10067-005-0130-0 
  8. Sturrock RD, Hart FD (1974) Double-blind cross-over comparison of     indomethacin, flurbiprofen, and placebo in ankylosing spondylitis Ann Rheum Dis 33(2):129-131
  9.  Gran JT (1985) An epidemiological survey of the signs and symptoms of ankylosing spondylitis. Clin Rheumatol 4(2): 161-169
  10. Gran JT, Husby G, Hordvik M (1985) Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, Northern Norway. Ann Rheum Dis 44(6):359-367
  11. Alamanos Y, Papadopoulos NG, Voulgari PV, Karakatsanis A, Siozos C, Drosos AA (2004) Epidemiology of ankylosing spondylitis in Northwest Greece, 1983-2002.Rheumatology 43(5):615-618
  12. Braun J, Pincus T (2002) Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 20[6 Suppl 28]:S16–S22
  13. Hardo PG, Chalmers DM, Jakeways M, Wright V, Axon AT (1993) Management of NSAIDs-related dyspepsia in the community. Br J Clin Pract 47(5):241–242
  14. Singh G (1998) Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 105(1B):31S–38S
  15. Richy F, Bruyere O, Ethgen O, Rabenda V, Bouvenot G, Audran M, Herrero-Beaumont G, Moore A, Eliakim R, Haim M, Reginster JY (2004) Time-dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 63(7):759–766
  16. Feldtkeller E, Bruckel J, Khan MA (2000) Scientific contributions of ankylosing spondylitis patient advocacy groups. Curr Opin Rheumatol 12:239–247
  17. Feldtkeller E (1999) Erkrankungsalter und Diagnoseverzöger- ung bei Spondylarthropathien. Z Rheumatol 58:21–30
  18. Feldtkeller E, Lemmel EM (1999) Zur Situation von Spondy- loarthritis-Patienten. Ergebnisse einer Repräsentativbefragung der Deutschen Vereinigung Morbus Bechterew. Novartis Pharma, Nurembergvan der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27 (4):361–368 
  19. Gran JT (1985) An epidemiological survey of the signs and symptoms of ankylosing spondylitis. Clin Rheumatol 4(2):161– 169
  20. Braun J, Sieper J: Ankylosing spondylitis. Lancet. 2007, 369:1379-90. 10.1016/S0140-6736(07)60635-7 
  21. Sieper J, Rudwaleit M, Baraliakos X, et al.: The Assessment of SpondyloArthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009, 68 Suppl 2:ii1-44. 10.1136/ard.2008.104018 
  22. Ward MM, Deodhar A, Akl EA, et al.: American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2016, 68:282-98. 10.1002/art.39298 
  23. Chopra A: Disease burden of rheumatic diseases in India: COPCORD perspective. Indian J Rheumatol. 2015, 10:70-7. 10.1016/j.injr.2015.04.002
  24. Chopra A, Shankar S: Biosimilar DMARD in rheumatology: a general perspective with a focus on India. Indian J Rheumatol. 2012, 7:89-96. 10.1016/j.injr.2012.04.005 
  25. Kay J, Smolen JS: Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis. 2013, 72:1589-93. 10.1136/annrheumdis-2012-203198
  26. Bandyopadhyay S, Mahajan M, Mehta T, et al.: Physicochemical and functional characterization of a biosimilar adalimumab ZRC-3197. Biosimilars. 2014, 1:1-18. 10.2147/BS.S75573
  27. Exemptia™ (adalimumab). (2023). Accessed: February 23, 2023: https://exemptia.com/adalimumabindia.html.
  28. Chopra A, Lagoo-Joshi V, Kunjeer V: Our experience with anti-TNF therapy - a choice between the devil and the deep sea. APLAR J Rheumatol. 2005, 9:A208. 
  29. Clinical effectiveness of adalimumab (Exemptia™) in patients suffering from symptomatic ankylosing spondylitis (AS) under supervised standard rheumatology care. (2023). Accessed: February 23, 2023: https://ctri.nic.in/Clinicaltrials/pdf_generate.php? trialid=19498&EncHid=&modid=&compid=','19498det%
  30. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A: A new approach to defining disease status in ankylosing spondylitis.

Photo
R. Meghana
Corresponding author

Bhaskar Pharmacy College, Yenakapally, Moinabad

Photo
A. V. Kishore Babu
Co-author

Bhaskar Pharmacy College, Yenakapally, Moinabad

Photo
A. Srinivasa Rao
Co-author

Bhaskar Pharmacy College, Yenakapally, Moinabad

R. Meghana, A. V. Kishore Babu, A. Srinivasa Rao, Advances Of NSAIDS In Ankylosing Spondylitis, Int. J. in Pharm. Sci., 2023, Vol 1, Issue 9, 379-384. https://doi.org/10.5281/zenodo.8361827

More related articles
A Review Of The Impact Of Different Herbs As An An...
Shyam Rangari, Divyanshu Gahane, Aishwarya Deshmukh, Milind Umeka...
Extraction, Phytochemical Investigation and Antimi...
Ganesh D. Barkade, Akshata B. Sinare, Mayur G. Tandale, Rutuja B....
Formulation and Evaluation Of Polyherbal Scrub For...
Komal R. Deshmukh, Komal R. Ghavate , Vaibhav S. Goud, Harshada P...
A Comprehensive Review Of Gestational Diabetes Mellitus...
Kaula, Vineetha K, Ramakrishna Shabaraya A, ...
Review On Various Analytical Approaches For The Estimation Of Rilpivirine And It...
Chaganti soujanya, Srinija Naluka, Karuna Devi Barla, Durga Panikumar Anumolu, ...
Related Articles
A Comparative Study of Diabetic Treatment – Allopathy vs. Ayurveda...
Angad Bhaskar Newre, Abhay S. Jejurkar, Akash S. Pagar, Akshay S. Gavali, Dr. Rajendra M. Kawde, ...
A Study on OTC products in India and Europe: Market Prospective...
Dheeraj Kotagiri, Dr. Bhavana B Bhat, Venkateswara Raju, K. Krishna Teja, K. Jnanendra Kumar, M. Jee...
In Vitro Anti inflammatory Activity Of Glochidion Zeylanicum A. Juss. Leaves Ext...
Eknath V. Unde , Sneha B. Fand , Amol S. Darade , Ganesh R. Gosavi, Archana S. Murgunde, ...
A Review Of The Impact Of Different Herbs As An Anti Asthmatics...
Shyam Rangari, Divyanshu Gahane, Aishwarya Deshmukh, Milind Umekar, ...
More related articles
A Review Of The Impact Of Different Herbs As An Anti Asthmatics...
Shyam Rangari, Divyanshu Gahane, Aishwarya Deshmukh, Milind Umekar, ...
Extraction, Phytochemical Investigation and Antimicrobial Activity of Hibiscus R...
Ganesh D. Barkade, Akshata B. Sinare, Mayur G. Tandale, Rutuja B. Sonawane, Rutuja R. Sumbe, ...
Formulation and Evaluation Of Polyherbal Scrub For pigmentation ...
Komal R. Deshmukh, Komal R. Ghavate , Vaibhav S. Goud, Harshada Palodkar , Rupali Tasgoankar , ...
A Review Of The Impact Of Different Herbs As An Anti Asthmatics...
Shyam Rangari, Divyanshu Gahane, Aishwarya Deshmukh, Milind Umekar, ...
Extraction, Phytochemical Investigation and Antimicrobial Activity of Hibiscus R...
Ganesh D. Barkade, Akshata B. Sinare, Mayur G. Tandale, Rutuja B. Sonawane, Rutuja R. Sumbe, ...
Formulation and Evaluation Of Polyherbal Scrub For pigmentation ...
Komal R. Deshmukh, Komal R. Ghavate , Vaibhav S. Goud, Harshada Palodkar , Rupali Tasgoankar , ...